Compare PTCT & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | CSTM |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | France |
| Employees | 991 | 11500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | 2006 | 2012 |
| Metric | PTCT | CSTM |
|---|---|---|
| Price | $63.29 | $25.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 4 |
| Target Price | ★ $80.65 | $30.75 |
| AVG Volume (30 Days) | 918.2K | ★ 1.3M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 264.48 | ★ 405.26 |
| EPS | 0.90 | ★ 1.42 |
| Revenue | $264,734,000.00 | ★ $8,449,000,000.00 |
| Revenue This Year | N/A | $21.46 |
| Revenue Next Year | $17.70 | $0.50 |
| P/E Ratio | $69.20 | ★ $17.35 |
| Revenue Growth | ★ 36.19 | 15.19 |
| 52 Week Low | $58.90 | $14.45 |
| 52 Week High | $90.87 | $36.99 |
| Indicator | PTCT | CSTM |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 38.39 |
| Support Level | N/A | $22.10 |
| Resistance Level | $68.93 | $27.18 |
| Average True Range (ATR) | 1.97 | 0.71 |
| MACD | -0.32 | -0.05 |
| Stochastic Oscillator | 22.43 | 17.56 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.